The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
The findings support blood free carnitine as a reliable test for the early detection of mild cognitive impairment likely to develop Alzheimer disease, especially in women, and as a proxy to disease progression and CSF markers in diagnosed Alzheimer disease.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
The diminished carnitine levels were strongly predictive of changes in the cerebrospial fluid CSF tied to the progression of Alzheimer disease and Lewy Body Dementia LBD, elevated Tau protein and lower soluble ameloid Aβ42 (amyloid solubility decreases as the disease progresses, leading to its clumping and buildup between neurones).
Free carnitine as well as its precursor LAC were significantly reduced in both women and men with diagnosed Alzheimer disease.